[{"orgOrder":0,"company":"Beacon Discovery","sponsor":"Eurofins CDMO","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Beacon Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Beacon Discovery \/ Eurofins","highestDevelopmentStatusID":"2","companyTruncated":"Beacon Discovery \/ Eurofins"}]

Find Clinical Drug Pipeline Developments & Deals by Beacon Discovery

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Eurofins acquired Beacon Discovery for its innovative approach, years of experience in drug discovery and development as well as their profound expertise in GPCR research, complemented by their unique compound library.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 18, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Eurofins CDMO

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank